Zeteletinib hemiadipate

Description: Zeteletinib hemiadipate (BOS-172738, DS-5010) is an orally active compound that functions as a selective inhibitor of RET kinase. It exhibits nanomolar potency against RET and a 300-fold selectivity towards VEGFR2. Notably, Zeteletinib hemiadipate demonstrates exceptional effectiveness against various forms of RET, including the wild type, RET V804M/L gatekeeper mutants, and the oncogenic RET mutation M918T. Additionally, Zeteletinib hemiadipate exerts potent antitumor effects. Target: Others. Smiles: OC(=O)CCCCC(O)=O.COc1cc2cc(cnc2cc1OC)-c1ccc(CC(=O)Nc2cc(no2)C(C)(C)C(F)(F)F)cn1.COc1cc2cc(cnc2cc1OC)-c1ccc(CC(=O)Nc2cc(no2)C(C)(C)C(F)(F)F)cn1. References: Yasuyuki Kaneta, et al.Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor. MOLECULAR CANCERTHER APEUTICS. January 2018, Volume 17, Issue 1.